The Latest in ASTCT Advocacy: April 2024
CMS Expands Coverage for Allogeneic HSCT in MDS Patients
The Centers for Medicare & Medicaid (CMS) Services revised the National Coverage Determination (NCD) of allogeneic hematopoietic stem cell transplantation (HSCT) for individuals with myelodysplastic syndromes (MDS) in response to a request from ASH, ASTCT, NMDP, and CIBMTR. The NCD expands coverage for Medicare patients with myelodysplastic syndromes (MDS), a critical step in providing access to life-saving treatment. Allogeneic HSCT is the sole curative therapy for MDS, a group of blood disorders affecting primarily older adults.
Biden Cancer Moonshot: Expanding Cancer Navigation Services for 150M Americans
The Biden Cancer Moonshot marks significant progress with commitments from leading health insurers and oncology providers to expand navigation services to over 150 million Americans, aiding those with complex health conditions like cancer. Seven major health insurers including Aetna and Humana, serving nearly half the nation, will offer navigation services. Additionally, 40 cancer centers and practices pledge to utilize new codes to provide navigation services.
Join ASTCT's Hill Day this September
ASTCT encourages all members to actively engage and explore opportunities for involvement. The upcoming Hill Day is scheduled for September 9-10. ASTCT recognizes the importance of collective action in advancing advocacy goals. Leading to the ASTCT Hill Day, we will share ways you can lend your voice to our advocacy efforts. Visit the ASTCT website to learn more about the ASTCT Hill Day and how you can participate in September.